Third Xiangya Hospital

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants

  NCT07906691· Phase 1· Shanghai Hengrui Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis

  NCT07909655· Phase 2· Shanghai Huaota Biopharmaceutical Co., Ltd.· Source

• Recruiting

  Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis

  NCT07755956· Phase 1· Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.· Source

• Not yet recruiting

  Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer

  NCT07882628· Beijing Chao Yang Hospital· Source

• Recruiting

  Study of UBT37034 Injection

  NCT07873645· Phase 1· The United Bio-Technology (Hengqin) Co., Ltd.· Source

• Not yet recruiting

  Online Tai Chi Versus Digital CBT-I for Chronic Insomnia

  NCT07853651· The Third Xiangya Hospital of Central South University· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis

  NCT07724366· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

  NCT07691515· Phase 3· Zhejiang Cancer Hospital· Source

• Not yet recruiting

  A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

  NCT07833098· Phase 2· Zhejiang Yangli Pharmaceutical Technology Co., Ltd.· Source

• Recruiting

  To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.

  NCT07760467· Phase 1· Zhuhai United Laboratories Co., Ltd.· Source

• Not yet recruiting

  Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

  NCT07741045· Phase 3· Hangzhou PhecdaMed Co., Ltd.· Source

• Active, not recruiting

  Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets

  NCT07608666· Phase 1· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities

  NCT07781124· Vantive Health LLC· Source

• Recruiting

  Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer

  NCT07886229· Phase 1· Second Xiangya Hospital of Central South University· Source

• Not yet recruiting

  Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

  NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer

  NCT07886047· Phase 1· Second Xiangya Hospital of Central South University· Source

• Recruiting

  Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer

  NCT07529626· Shanghai Zhongshan Hospital· Source

• Recruiting

  A Clinical Study of Cizutamig in Thyroid Eye Disease

  NCT07597200· Phase 1· Candid Therapeutics· Source

• Enrolling by invitation

  Precision Antithrombotic Therapy

  NCT07654634· The Third Xiangya Hospital of Central South University· Source

• Recruiting

  ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

  NCT06951646· Phase 2· Second Xiangya Hospital of Central South University· Source

• Recruiting

  A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）

  NCT07368608· Phase 1/2· BeBetter Med Inc· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

  NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

  NCT07265570· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

  NCT07182682· Phase 3· Dizal (Jiangsu) Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

  NCT07217301· Phase 3· Takeda· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

  NCT07160335· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease

  NCT07123207· The Third Xiangya Hospital of Central South University· Source

• Recruiting

  The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

  NCT07172035· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study

  NCT07034664· The Third Xiangya Hospital of Central South University· Source

• Recruiting

  A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

  NCT06933472· Phase 3· Alebund Pharmaceuticals· Source

• Active, not recruiting

  A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases

  NCT06786338· Phase 2· Suzhou Sanegene Bio Inc.· Source

• Recruiting

  Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study

  NCT07093294· The Third Xiangya Hospital of Central South University· Source

• Recruiting

  Establishment of a Classification System and Postoperative Risk Warning Model for Patients Undergoing Bariatric Metabolic Surgery for Severe Obesity

  NCT07093502· The Third Xiangya Hospital of Central South University· Source

• Not yet recruiting

  Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

  NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Not yet recruiting

  A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

  NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Recruiting

  Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

  NCT07152041· Phase 3· Institute of Hematology & Blood Diseases Hospital, China· Source

• Recruiting

  Newly-diagnosed Pediatric T-cell ALL Protocol

  NCT06855810· Phase 2/3· Institute of Hematology & Blood Diseases Hospital, China· Source

• Recruiting

  Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

  NCT06882057· Phase 2/3· Institute of Hematology & Blood Diseases Hospital, China· Source

• Not yet recruiting

  Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

  NCT06859931· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

  NCT06840704· Phase 3· Hunan Cancer Hospital· Source

• Active, not recruiting

  Changes in Fat and Muscle Tissue Function and Their Impact on Metabolic Health After Bariatric Surgery

  NCT07035483· Shaihong Zhu· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

Showing 50 of 86.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer13 recruiting
• Childhood cancers7 recruiting
• Obesity6 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Colorectal cancer4 recruiting
• Acute myeloid leukaemia3 recruiting
• Chronic kidney disease3 recruiting
• Crohn's disease3 recruiting
• Heart failure3 recruiting
• High blood pressure3 recruiting
• Stroke3 recruiting
• Coronary artery disease2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Type 2 diabetes2 recruiting
• Alzheimer disease1 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Endometriosis1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Graves' disease and hyperthyroidism1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Insomnia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Lupus (SLE)1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Multiple myeloma1 recruiting
• Obstructive sleep apnoea1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  HPP737 in Adult Patients With Plaque Psoriasis

  NCT07712731· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study

  NCT07249138· Children's Hospital of Fudan University· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Completed

  Treatment of Moderate to Severe Plaque Psoriasis

  NCT06542614· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Completed

  Evaluation of the Application of Intelligent Applications in Patients Undergoing Peritoneal Dialysis

  NCT07612124· The Third Xiangya Hospital of Central South University· Source

• Completed

  Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06415773· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

  NCT06350812· Phase 1/2· PegBio Co., Ltd.· Source

• Completed

  Effect of Lifestyle Intervention on Mobilization of Fat Storage and Iron Deposition in Obesity

  NCT06441409· The Third Xiangya Hospital of Central South University· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Terminated

  Amplatzer Amulet China Post Market Study (PMS)

  NCT06189365· Abbott Medical Devices· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Pfizer· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06353347· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source

• Completed

  A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

  NCT06973681· Phase 2· BrightGene Bio-Medical Technology Co., Ltd.· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

  NCT06061471· Phase 2· Akeso· Source

• Terminated

  A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

  NCT05849727· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

  NCT06974825· Phase 2· BrightGene Bio-Medical Technology Co., Ltd.· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

  NCT07712705· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

  NCT06066125· Phase 3· Akeso· Source

• Completed

  Study of Telitacicept in Generalized Myasthenia Gravis

  NCT05737160· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

  NCT05593575· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

  NCT05815862· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT05531682· Phase 2· Huabo Biopharm Co., Ltd.· Source

• Recruiting

  OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method

  NCT05450835· Nanfang Hospital, Southern Medical University· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

  NCT05400369· Phase 4· Daiichi Sankyo· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

  NCT05352516· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

  NCT05600309· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

  NCT05371652· Phase 3· Pfizer· Source

• Completed

  PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

  NCT05864105· Phase 2· Biotheus Inc.· Source

• Completed

  Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

  NCT05197842· Phase 1/2· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

  NCT06035354· Phase 1/2· Akeso· Source

• Completed

  Phase III Study on HMPL-523 for Treatment of ITP

  NCT05029635· Phase 3· Hutchmed· Source

• Completed

  A Study of Vedolizumab in Adults in Real-World Practice

  NCT04872491· Takeda· Source

• Completed

  Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction

  NCT04944706· Phase 2· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

  NCT05092841· Phase 3· Tasly GeneNet Pharmaceuticals Co., Ltd· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04939142· Phase 3· Antengene Corporation· Source

• Completed

  Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

  NCT05359068· Phase 3· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

  NCT04847557· Phase 3· Eli Lilly and Company· Source

Showing 50 of 66.

Conditions

Diseases this institution publishes on or runs trials for.

• Crohn's disease32 works · 6 trials
• Atopic dermatitis (eczema)26 works · 3 trials
• Vitiligo6 works · 0 trials
• Charcot-Marie-Tooth disease5 works · 1 trial
• Trigeminal neuralgia3 works · 0 trials